An Open Single Centre Study to Evaluate the Long-term Antibody Persistence and Immune Memory Between 16 and 20 Years After the Primary Study HAB-032 (208127/022) in Which Healthy Adults Were Vaccinated With Twinrix Adult Following a Three-dose Schedule.

Trial Profile

An Open Single Centre Study to Evaluate the Long-term Antibody Persistence and Immune Memory Between 16 and 20 Years After the Primary Study HAB-032 (208127/022) in Which Healthy Adults Were Vaccinated With Twinrix Adult Following a Three-dose Schedule.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Dec 2015

At a glance

  • Drugs Hepatitis A-hepatitis B vaccine (Primary)
  • Indications Hepatitis A; Hepatitis B
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
  • Most Recent Events

    • 21 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 06 Mar 2015 Planned End Date changed from 1 Apr 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
    • 06 Mar 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top